il-3
Neoplasm Metastasis
National Cancer Institute (NCI)Phase 1Dormant
CC
42/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 73/ 100
Competitive context
171 Active assets in the Neoplasm Metastasis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Eloxatin Ruijin Hospital | Phase 4 | BBB |
FLUOROURACILUM Ruijin Hospital | Phase 4 | BBB |
Irinotecan Eli Lilly and Company | Phase 4 | BBB |
DEXAMETHASONE Janssen Research & Development, LLC | Phase 2 | BBB |
Atezolizumab UNC Lineberger Comprehensive Cancer Center | Phase 2/3 | BB |
View all 50 →
Same molecule, other indications
il-3 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →